ORIENTBIO 2026 Business Report: Net Loss Deepens to 45.7 Billion Won, Capital Erosion, Stock Split and Treasury Disposal Impact Shareholder Value

ORIENTBIO's 69th business report shows revenue of 29.7 billion won, up 1% year-on-year, but operating loss widened to 4.1 billion won and net loss reached 4.6 billion won, leading to capital erosion.
The operating loss was driven by higher cost of goods sold and increased bad debt expenses, while losses from equity-method investments further pressured profitability.
No dividends were paid; the company disposed of 14,879 treasury shares to the largest shareholder, slightly increasing outstanding shares without material dilution. After the period, a 2-for-1 stock split was approved to halve outstanding shares and stabilize the stock price.
The debt ratio is low at 19%, but retained earnings turned negative, indicating capital erosion. Cash and cash equivalents stood at 5.8 billion won, providing short-term liquidity.
A lawsuit for 338 million won was filed by the Korea Research Institute of Bioscience and Biotechnology, and contingent liabilities exist from the sale of US subsidiary OBRC.
[AI Summary]ORIENTBIO's financial structure is weak due to persistent operating losses and capital erosion, with high reliance on related-party transactions. While the stock split may provide short-term price support, sustainable shareholder value recovery is unlikely without fundamental profitability improvement.